Bill Ackman Eyes New Fund to Bet Against Market Complacency 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
HOPKINTON, Mass., Feb. 06, 2017 -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases today announced that Martin Driscoll, President and Chief Executive Officer, will present at the 19th Annual BIO CEO & Investor Conference on Monday, February 13, 2017, at 5:00 p.m. Eastern Time in the Louis XVI presentation room. The conference is being held at the Waldorf Astoria Hotel in New York City.
Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
Management will be available to meet with investors throughout the day. Investors wishing to schedule a meeting should contact Spring Bank at [email protected].
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus. SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, which have been implicated in the body’s immune response to viral infections. Spring Bank believes that SB 9200 may play an important role in antiviral therapy by modulating the body’s immune response through its mechanisms of action to fight viral infections such as HBV. For more information please visit: www.springbankpharm.com.
Contact: Jon Freve Chief Financial Officer Spring Bank Pharmaceuticals (508) 473-5993 [email protected]
